Drugs / VIR-1388
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05854381 | Sep 2023 → Sep 2025 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-09-20 | Vir Biotechnology, Inc. | Vir Biotechnology Announces First Participant Dosed in New Phase 1 Trial Evaluating VIR-1388, an Investigational T Cell Vaccine for the Prevention of HIV vir.bio ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VIR-1388 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05854381 ↗ |
| Modality | Vaccine | “the HCMV-HIV Vaccine Candidate VIR-1388” NCT05854381 ↗ |
| Route | Subcutaneous | “VIR-1388 is given by subcutaneous injection” NCT05854381 ↗ |